These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11734111)

  • 1. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
    Russo P; Loprevite M; Cesario A; Ardizzoni A
    Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD
    Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
    Sebti SM; Hamilton AD
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
    Adjei AA
    Lung Cancer; 2003 Aug; 41 Suppl 1():S55-62. PubMed ID: 12867063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.
    Morgan MA; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1482-98. PubMed ID: 12886235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors: mechanism and applications.
    Prendergast GC; Rane N
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS inhibitors: potential for cancer therapeutics.
    Kloog Y; Cox AD
    Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
    Moasser MM; Rosen N
    Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors.
    Sebti SM; Adjei AA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.